ArticleWorld journal of oncology2025
Understanding the Role of All-Trans Retinoic Acid in Acute Myeloid Leukemia Cells.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferumoxytol enhances NF-κB-responsive GBA-targeted ferroptosis gene therapy in acute myeloid leukemia.Journal of nanobiotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: All-trans retinoic acid (ATRA) has revolutionized the management of acute promyelocytic leukemia (APL) and has generated interest in differentiation therapy as means to reduce reliance on conventional chemotherapy in other subtypes of acute myeloid leukemia (AML). However, the precise relationship between immunophenotypic changes and morphological maturation during ATRA-induced differentiation remains poorly defined. This study aimed to investigate the phenotypic and morphological progression of HL60 cells treated with ATRA and to establish quantitative correlations between surface marker expression and cell morphology. Methods: HL60 cells were treated with 1 µM ATRA. Expression of myeloid and monocytic surface markers (CD38, CD45, CD11b, human leukocyte antigen (HLA)-DR, CD15, CD13, CD33) was analyzed in parallel with morphological assessment using Giemsa-stained cytospin preparations. Pearson correlation analysis was applied to link surface marker expression with specific stages of granulocytic differentiation. In addition, the mRNA expression of myeloid-specific transcription factors Results: ATRA induced a stepwise maturation of HL60 cells from promyelocytes through metamyelocytes and band forms to segmented neutrophils, recapitulating physiological granulopoiesis. Acquisition of mature morphology correlated positively with CD38, CD45, CD11b, HLA-DR, and CD15 expression, while CD13 and CD33 were progressively downregulated and inversely correlated with differentiation. Importantly, this study established quantitative links between distinct immunophenotypic signatures and defined morphological stages, a relationship not clearly demonstrated in previous HL60 studies. Concomitantly, ATRA upregulated transcription factors Conclusions: Our study reveals that ATRA not only promotes broad differentiation of HL60 cells but also orchestrates a targeted reprogramming that synchronizes morphological maturation with distinct immunophenotypic shifts, mediated by transcriptional upregulation of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.